$Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor$
Código QR

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Nisha S Joseph,1 Yu-Tzu Tai,2 Kenneth C Anderson,2 Sagar Lonial1 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 2Dana-Farber Cancer Institute, Harvard University, Boston, MA, USACorrespondence: Kenneth C AndersonDana-Farber Cancer Institute, Blood Compont, D289, 44...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joseph NS, Tai YT, Anderson KC, Lonial S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	belantamab mafodotin belamaf selinexor relapsed/refractory myeloma myeloma Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0d721601a192472480532b05603dd0e1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d721601a192472480532b05603dd0e1
record_format	dspace
spelling	oai:doaj.org-article:0d721601a192472480532b05603dd0e12021-12-02T16:45:44ZNovel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor1179-1438https://doaj.org/article/0d721601a192472480532b05603dd0e12021-08-01T00:00:00Zhttps://www.dovepress.com/novel-approaches-to-treating-relapsed-and-refractory-multiple-myeloma--peer-reviewed-fulltext-article-CPAAhttps://doaj.org/toc/1179-1438Nisha S Joseph,1 Yu-Tzu Tai,2 Kenneth C Anderson,2 Sagar Lonial1 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 2Dana-Farber Cancer Institute, Harvard University, Boston, MA, USACorrespondence: Kenneth C AndersonDana-Farber Cancer Institute, Blood Compont, D289, 44 Binney St, Boston, MA, 02115, USATel +1 617 632-2569Email kenneth_anderson@dfci.harvard.eduAbstract: Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action. Here, we will review the most recent data on both belantamab mafodotin, an antibody drug conjugate (ADC) targeting BCMA, and selinexor, a first-in-class selective inhibitor of XPO1, as well as touch on some of the recently published data for other immunotherapies in development, namely bispecific T cell engagers, ADCs, and CAR-T cell therapies.Keywords: belantamab mafodotin, belamaf, selinexor, relapsed/refractory myeloma, myelomaJoseph NSTai YTAnderson KCLonial SDove Medical Pressarticlebelantamab mafodotinbelamafselinexorrelapsed/refractory myelomamyelomaTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 13, Pp 169-180 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	belantamab mafodotin belamaf selinexor relapsed/refractory myeloma myeloma Therapeutics. Pharmacology RM1-950
spellingShingle	belantamab mafodotin belamaf selinexor relapsed/refractory myeloma myeloma Therapeutics. Pharmacology RM1-950 Joseph NS Tai YT Anderson KC Lonial S Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
description	Nisha S Joseph,1 Yu-Tzu Tai,2 Kenneth C Anderson,2 Sagar Lonial1 1Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 2Dana-Farber Cancer Institute, Harvard University, Boston, MA, USACorrespondence: Kenneth C AndersonDana-Farber Cancer Institute, Blood Compont, D289, 44 Binney St, Boston, MA, 02115, USATel +1 617 632-2569Email kenneth_anderson@dfci.harvard.eduAbstract: Though survival outcomes in multiple myeloma patients have improved drastically over the past few decades, there still remains an ongoing need for effective and tolerable treatment options in the relapsed and refractory space. Encouragingly, there have been three recent FDA approvals for triple-class refractory multiple myeloma, and there is promising ongoing development of additional agents with varying novel mechanisms of action. Here, we will review the most recent data on both belantamab mafodotin, an antibody drug conjugate (ADC) targeting BCMA, and selinexor, a first-in-class selective inhibitor of XPO1, as well as touch on some of the recently published data for other immunotherapies in development, namely bispecific T cell engagers, ADCs, and CAR-T cell therapies.Keywords: belantamab mafodotin, belamaf, selinexor, relapsed/refractory myeloma, myeloma
format	article
author	Joseph NS Tai YT Anderson KC Lonial S
author_facet	Joseph NS Tai YT Anderson KC Lonial S
author_sort	Joseph NS
title	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
title_short	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
title_full	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
title_fullStr	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
title_full_unstemmed	Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
title_sort	novel approaches to treating relapsed and refractory multiple myeloma with a focus on recent approvals of belantamab mafodotin and selinexor
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/0d721601a192472480532b05603dd0e1
work_keys_str_mv	AT josephns novelapproachestotreatingrelapsedandrefractorymultiplemyelomawithafocusonrecentapprovalsofbelantamabmafodotinandselinexor AT taiyt novelapproachestotreatingrelapsedandrefractorymultiplemyelomawithafocusonrecentapprovalsofbelantamabmafodotinandselinexor AT andersonkc novelapproachestotreatingrelapsedandrefractorymultiplemyelomawithafocusonrecentapprovalsofbelantamabmafodotinandselinexor AT lonials novelapproachestotreatingrelapsedandrefractorymultiplemyelomawithafocusonrecentapprovalsofbelantamabmafodotinandselinexor
_version_	1718383436497944576

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor

Ejemplares similares